Alivus Life Sciences Ltd
ALIVUS
Company Profile
Business description
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
Contact
470, Cardinal Gracious Road
4th Floor, OIA House
Andheri (East)
MumbaiMH400 099
INDT: +91 2268297979
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,220
Stocks News & Analysis
stocks
We take a different view to market on ASX bloodbath
Sales growth at CSL was lower than expected but streamlining the business has its perks.
stocks
BHP earnings weaker with lower iron ore prices more than offsetting higher copper volumes
Results were softer than expected.
stocks
Moated ASX player makes moves to support growth in China
a2Milk announced an acquisition and a divestiture as it aims to take a bigger slice of China’s baby formula market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.70 | 3.90 | 0.04% |
| CAC 40 | 7,979.08 | 95.03 | 1.21% |
| DAX 40 | 24,423.07 | 108.30 | 0.45% |
| Dow JONES (US) | 44,922.27 | 10.45 | 0.02% |
| FTSE 100 | 9,189.22 | 31.48 | 0.34% |
| HKSE | 24,980.20 | 142.70 | -0.57% |
| NASDAQ | 21,314.95 | 314.82 | -1.46% |
| Nikkei 225 | 42,826.72 | 719.57 | -1.65% |
| NZX 50 Index | 13,102.06 | 173.38 | 1.34% |
| S&P 500 | 6,411.37 | 37.78 | -0.59% |
| S&P/ASX 200 | 8,916.90 | 20.70 | 0.23% |
| SSE Composite Index | 3,725.22 | 2.07 | -0.06% |